Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000100

Drug Information
NamePerphenazine    
SynonymsSpectrum2_001602; 2-Chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine; Decentan; BPBio1_000188; 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol; MLS001146929; 2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol; STK019818; 2-Chloro-10-3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl phenothiazine; C21H26ClN3OS; NCGC00015826-03; 1-Piperazineethanol, 4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-; 2-Chloro-10-(3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; SR-01000000137-4; D00503; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina [Italian]; BIDD:GT0150; Prestwick2_000125; 4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol; NCGC00024092-03; KBio2_002090; SPBio_001603; HMS2093M15; NCGC00015826-10; I06-1508; F-mon; DivK1c_000880; 4-(3-(2-Chlorophenothiazin-10-yl)propyl)-1-piperazineethanol; AI3-50151; Perphenan; HSDB 3379; CPD000058180; SMR000058180; C07427; 1-Piperazineethanol, 4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-; KBio2_004658; 58-39-9; Perphenazine (JP15/USP/INN); D010546; SPBio_002109; CAS-58-39-9; Trilifan; Perphenazin; Perphenazinum; NCGC00015826-02; BAS 00139131; 2-{4-[3-(2-Chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol; Trifaron; AB00052390; AC-12196; Trilafon; Etaperazine; Ethaperazine; NCGC00015826-06; SCH-3940; 2-Chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine; CHEMBL567; EU-0072164; Spectrum4_000843; P 6402; Prestwick0_000125; NCGC00015826-01; AKOS000664046; KBioGR_001445; NCGC00024092-04; KBio1_000880; BSPBio_000170; Perfenazina [Italian]; NCGC00024092-05; Perfenazine; Prestwick3_000125; CHEBI:8028; Spectrum3_000758; NSC150866; L000919; Piperazineethanol, 4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-; BSPBio_002376; NINDS_000880; 2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol; P6402_SIGMA; Triphenot; 1-(2-Hydroxyethyl)-4-(3-(2-chloro-10-phenothiazinyl)propyl)piperazine; UNII-FTA7XXY4EZ; Lopac0_000930; KBioSS_002090; 1-(2-Hydroxyethyl)-4-[3-(2-chloro-10-phenothiazinyl)propyl]piperazine; Prestwick_536; NSC 150866; IDI1_000880; .gamma.-[4-(.beta.-Hydroxyethyl)piperazin-1-yl]propyl-2-chlorophenothiazine; STOCK1S-21551; 1-Piperazineethanol, 4-(3-(2-chlorophenothiazin-10-yl)propyl)-; LS-112185; HMS1568I12; WLN: T C666 BN ISJ EG B3- AT6N DNTJ D2Q; Chlorpiprazine; Perphenazine [Trilafon]; Spectrum_001610; NCGC00024092-06; Sch 3940; Etaperazin; KBio3_001596; MolPort-001-727-942; SPECTRUM1503934; HMS1922M14; Fentazin; Lopac-P-6402; Perfenazina; Emesinal; SAM002264637; EU-0100930; MLS000069637; HMS502L22; Prestwick1_000125; EINECS 200-381-5; Perphenazine [INN:BAN:JAN]; Perphenazine maleate; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina; perphenazine; 2-Chloro-10-3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl phenothiazine; Chlorperphenazine; DB00850; Spectrum5_001493; Apo-Perphenazine; 1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-; 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol; Tranquisan; 1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-, trihydrochloride; Oprea1_603835; CID4748; BRD-K10995081-001-05-5; AC1L1IVB; Perphenazinum [INN-Latin]; nchembio873-comp26; Thilatazin; KBio2_007226; gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine; PZC; Perfenazina [INN-Spanish]    
Trade NameSiquil; Triavil    
CompanySchering-Plough Corporation    
IndicationSchizophrenia and bipolar disorderApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntipsychotic Agents    
CAS NumberCAS 58-39-9
FormularC21H26ClN3OS    
PubChem Compound IDCID 4748.    
PubChem Substance IDSID 9631.    
ChEBI8028;    
SuperDrug ATC IDN05AB03;    
SuperDrug CAS ID000058399;    
TargetD(2) dopamine receptorAntagonist[2][3]
Ref 1Methamphetamine Addiction and Abuse - Perphenazine To Reference
Ref 2CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93. To Reference
Ref 3A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology (Berl). 2004 Sep;175(2):148-53. Epub 2004 Mar 6. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543